论文部分内容阅读
目的比较甘精胰岛素联合阿卡波糖与二甲双胍联合达美康治疗冠心病并2型糖尿病患者的临床疗效。方法将50例冠心病并2型糖尿病患者随机分为甘精胰岛素联合阿卡波糖治疗组25例及二甲双胍联合达美康对照组25例,疗程为12周。定期测定并比较两组治疗前后空腹血糖(FPG)、餐后2h血糖(P2hBG)、糖化血红蛋白(A1C)、C反应蛋白(CRP)和体重指数(BMI)。结果治疗组FPG平均下降3.82mmol/L,对照组平均下降2.09mmol/L,两组P值均<0.01,降低的幅度有统计学意义(P<0.05);两种药物对P2hBG均有明显降低作用,治疗组平均下降5.12mmol/L,对照组平均下降4.10mmol/L,两组比较P2hBG降低的幅度有统计学意义(P<0.01);两组A 1C均能显著降低,治疗组从(9.83±1.50)%降至(6.64±0.55)%,对照组从(8.56±1.32)%降至(7.58±0.60)%,两组比较A1C降低的幅度有统计学意义(P<0.05),CRP两组均能显著降低,治疗组平均下降5.55mg/L,对照组平均下降3.52mg/L,两组比较CRP降低的幅度有统计学意义(P<0.05);治疗后12周治疗组BMI下降2.15%,对照组BMI下降2.35%,两组比较无统计学意义(P>0.05)。结论甘精胰岛素联合阿卡波糖治疗降低空腹和餐后血糖以及A1C、CRP、BMI的作用明显,甘精胰岛素联合阿卡波糖治疗冠心病并2型糖尿病患者有显著疗效。
Objective To compare the clinical efficacy of insulin glargine combined with acarbose and metformin in the treatment of coronary heart disease and type 2 diabetes mellitus. Methods Fifty patients with coronary heart disease and type 2 diabetes were randomly divided into 25 patients with glargine and acarbose and 25 patients with metformin and metconazole. The course of treatment was 12 weeks. The FPG, P2hBG, A1C, C-reactive protein (CRP) and body mass index (BMI) were measured and compared before and after treatment. Results The FPG of the treatment group decreased by 3.82mmol / L on average, but decreased by 2.09mmol / L on average in the control group, P <0.01, the decreasing extent was statistically significant (P <0.05); the two drugs significantly reduced P2hBG (P <0.01). The A 1C in both groups was significantly lower than that in the control group (5.12 mmol / L in the treatment group and 4.10 mmol / L in the control group) 9.83 ± 1.50)% to (6.64 ± 0.55)%, while the control group decreased from (8.56 ± 1.32)% to (7.58 ± 0.60)%, the reduction of A1C in both groups was statistically significant (P <0.05) Both groups were significantly reduced, the treatment group averaged 5.55mg / L, the average control group decreased 3.52mg / L, CRP reduction in both groups was statistically significant (P <0.05); BMI decreased 12 weeks after treatment 2.15%, while the control group BMI decreased 2.35%, no significant difference between the two groups (P> 0.05). Conclusion The combination of glargine and acarbose can reduce the fasting and postprandial blood glucose and the effect of A1C, CRP and BMI. Glargine and acarbose have a significant effect on coronary heart disease and type 2 diabetes.